(NASDAQ: IPSC) Century Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.
Century Therapeutics's earnings in 2026 is -$107,779,000.On average, 7 Wall Street analysts forecast IPSC's earnings for 2026 to be -$114,795,836, with the lowest IPSC earnings forecast at -$176,747,713, and the highest IPSC earnings forecast at -$73,855,294. On average, 7 Wall Street analysts forecast IPSC's earnings for 2027 to be -$102,279,212, with the lowest IPSC earnings forecast at -$157,305,464, and the highest IPSC earnings forecast at -$62,492,941.
In 2028, IPSC is forecast to generate -$93,207,365 in earnings, with the lowest earnings forecast at -$132,560,785 and the highest earnings forecast at -$60,599,216.